Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2
diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on …

The collected data have revealed the beneficial effects of dipeptidyl peptidase‐4 (DPP‐4)
inhibitors on the vascular endothelium, including vildagliptin. However, the involved …

Glucagon-like peptide-1 (GLP-1), a gut hormone secreted from L cells in the intestine in
response to food intake, not only augments glucosedependent insulin secretion from …

Vildagliptin is a stable inhibitor of dipeptidyl peptidase-IV, a responsible enzyme that mainly
inactivates glucagon-like peptide-1, and now one of the widely used agents for the treatment …

Results After a 12-week treatment, vildagliptin-treated rats showed a significant reduction in
blood glucose and blood lipid levels. Moreover, vildagliptin recovered aortic endothelial …

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …

Hyperglycemia or high blood sugar is one of the major pathological characteristics of
diabetes. The endothelium is the inner layer of the vascular wall and is directly exposed to …

Background/Aims: Vildagliptin is an oral inhibitor of dipeptidyl peptidase-4, an enzyme
mainly responsible for inactivating incretins, and one of the widely used drugs for the …

Endothelial dysfunction is an early step to the progression of cardiovascular diseases in
diabetes. Apart from their anti-diabetic action, DPP-4 (dipeptidyl peptidase-4) inhibitors also …

Purpose Vildagliptin has been shown to prevent microvascular complications during
diabetes. The aim of this research was to evaluate the antioxidant effects of vildagliptin in …